Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients
Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients
复制标题
DOI：
10.1016/j.beha.2011.04.002
复制
发表时间：
2011-09-01
影响因子：
2.1
通讯作者：
Huang, Xiao-Jun
中科院分区：
文献类型：
--
作者：
Huang, Xiao-Jun
目前，人类白细胞抗原（HLA）匹配/单倍同种异体移植已被验证为无法立即获得HLA匹配相关或无关供体的患者的替代干细胞来源。然而，在HLA不匹配/单倍性造血干细胞移植（HSCT）后，复发仍然是一个挑战，该干细胞移植（HSCT）用于治疗血液恶性肿瘤的患者。近年来，新开发的免疫调节策略包括预防性和治疗性供体淋巴细胞/天然杀伤（NK）细胞输注，基于NK同种异体反应性/非遗传性母体抗原（NIMA）的供体选择，免疫重新机构的促进和应用， ，使降低复发率并改善单倍性之后的结果成为可能HSCT。进一步阐明了控制白血病干细胞在单倍性HSCT后免疫监视的基本机制可能会扩大我们的理解并导致控制复发的疗法。 （c）2011 Elsevier Ltd.保留所有权利。
Currently, human leukocyte antigen (HLA)-mismatched/haploidentical allografts have been validated as an alternative stem cell source for patients who have no immediate access to an HLA-matched related or unrelated donor. However, relapse remains a challenge after HLA-mismatched/haploidentical hematopoietic stem cell transplantation (HSCT) that is employed in the treatment of patients with hematological malignancies. In recent years, newly developed immunomodulatory strategies, which include prophylactic and therapeutic donor lymphocyte/natural killer (NK) cell infusion, donor selection based on NK alloreactivity/non-inherited maternal antigen (NIMA), immune reconstitution promotion, and application of exogenous cytokines, have made it possible to decrease the relapse rate and improve outcomes following haploidentical HSCT. Further elucidation of the underlying mechanisms that govern leukemia stem cell escape from immunosurveillance after haploidentical HSCT may broaden our understanding and lead to therapies that control relapse. (C) 2011 Elsevier Ltd. All rights reserved.